Skip to main content
SpringerLink
Log in

Clinical Strategies for Chemoprevention of Liver Cancer

  • Chapter
Cancer Chemoprevention

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

  • 842 Accesses

Abstract

Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma, hepatoblastoma, and other rare tumors of mesodermal origin such as angiosarcoma. The terms “primary liver cancer” and “hepatocellular carcinoma” are often used interchangeably in the literature. HCC accounts for 70–85% of primary liver cancers (1), and although intrahepatic cholangiocarcinoma is rare, it accounts for 5–30% of all liver cancers (2). Hepatoblastoma, a rare tumor that occurs only in children, represents approximately 1% of childhood cancers (3). This chapter will focus on HCC; cholangiocarcinoma, hepatoblastoma, and primary malignancies of mesodermal origin that develop in the liver will not be addressed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Serag HB. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2001;5:87–107.

    Article  PubMed  Google Scholar 

  2. Colombari R, Tsui WM. Biliary tumors of the liver. Semin Liver Dis 1995;15:402–413.

    PubMed  CAS  Google Scholar 

  3. Pappo AS, Rodriguez-Galindo C, Dome JS, Santana VM. Pediatric tumors. In Clinical Oncology, 2nd ed. Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE, eds. Churchill Livingstone, New York, 2000: pp. 2346–2401.

    Google Scholar 

  4. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide. Version 1.0. ed: IARC CancerBase No. 5. IARC Press, Lyon, 2001.

    Google Scholar 

  5. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999;19:271–285.

    PubMed  CAS  Google Scholar 

  6. Yu MW, Cheng SW, Lin MW, et al. Androgen-receptor gene CAG repeats, plasma testosterone levels, and risk of hepatitis B-related hepatocellular carcinoma. J Natl Cancer Inst 2000;92:2023–2028.

    Article  PubMed  CAS  Google Scholar 

  7. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2001;34:1225–1241.

    Article  PubMed  CAS  Google Scholar 

  8. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998;75:347–354.

    Article  PubMed  CAS  Google Scholar 

  9. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000;20:17–35.

    Article  PubMed  CAS  Google Scholar 

  10. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825–832.

    Article  PubMed  CAS  Google Scholar 

  11. Harris DR, Gonin R, Alter HJ, et al. The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse. Ann Intern Med 2001;134:120–124.

    PubMed  CAS  Google Scholar 

  12. Ikeda K, Saitoh S, Suzuki Y, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998;28:930–938.

    Article  PubMed  CAS  Google Scholar 

  13. Aizawa Y, Shibamoto Y, Takagi I, et al. Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C. A long term follow-up study after histologic diagnosis. Cancer 2000;89:53–59.

    Article  PubMed  CAS  Google Scholar 

  14. Colombo M. Hepatitis C virus and hepatocellular carcinoma. Semin Liver Dis 1999;19:263–269.

    PubMed  CAS  Google Scholar 

  15. Jackson PE, Groopman JD. Aflatoxin and liver cancer. Baillieres Best Pract Res Clin Gastroenterol 1999;13:545–555.

    Article  PubMed  CAS  Google Scholar 

  16. Ross RK, Yuan JM, Yu MC, et al. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 1992;339:943–946.

    Article  PubMed  CAS  Google Scholar 

  17. Qian GS, Ross RK, Yu MC, et al. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People’s Republic of China. Cancer Epidemiol Biomarkers Prev 1994;3:3–10.

    PubMed  CAS  Google Scholar 

  18. Wang LY, Hatch M, Chen CJ, et al. Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan. Int J Cancer 1996;67:620–625.

    Article  PubMed  CAS  Google Scholar 

  19. Yu MW, Lien JP, Chiu YH, et al. Effect of aflatoxin metabolism and DNA adduct formation on hepatocellular carcinoma among chronic hepatitis B carriers in Taiwan. J Hepatol 1997;27:320–330.

    Article  PubMed  CAS  Google Scholar 

  20. Montesano R, Hainaut P, Wild CP. Hepatocellular carcinoma: from gene to public health. J Natl Cancer Inst 1997;89: 1844–1851.

    Article  PubMed  CAS  Google Scholar 

  21. Kensler TW, Groopman JD, Roebuck BD. Use of aflatoxin adducts as intermediate endpoints to assess the efficacy of chemopreventive interventions in animals and man. Mutat Res 1998;402:165–172.

    PubMed  CAS  Google Scholar 

  22. Wild CP, Turner PC. Exposure biomarkers in chemoprevention studies of liver cancer. IARC Sci Publ 2001;154:215–222.

    PubMed  CAS  Google Scholar 

  23. Di Bisceglie AM, Carithers RL Jr, Gores GJ. Hepatocellular carcinoma. Hepatology 1998;28:1161–1165.

    Article  PubMed  Google Scholar 

  24. Niederau C, Fischer R, Sonnenberg A, et al. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985;313:1256–1262.

    PubMed  CAS  Google Scholar 

  25. Bradbear RA, Bain C, Siskind V, et al. Cohort study of internal malignancy in genetic hemochromatosis and other chronic nonalcoholic liver diseases. J Natl Cancer Inst 1985;75:81–84.

    PubMed  CAS  Google Scholar 

  26. Park SZ, Nagorney DM, Czaja AJ. Hepatocellular carcinoma in autoimmune hepatitis. Dig Dis Sci 2000;45:1944–1948.

    Article  PubMed  CAS  Google Scholar 

  27. Norris J, King D. Carcinogenesis. In Basic Science of Cancer. Kruh GD, Tew KD, eds. Current Medicine, Inc., Philadelphia; 2000; pp. 154–167.

    Google Scholar 

  28. Perantoni AO. Carcinogenesis. In McKinnell RG, Parchment RE, Perantoni AO, Barry PG, eds. The Biological Basis of Cancer. Cambridge University Press, New York, 1998; pp. 79–114.

    Google Scholar 

  29. Ozturk M. Genetic aspects of hepatocellular carcinogenesis. Semin Liver Dis 1999;19:235–242.

    PubMed  CAS  Google Scholar 

  30. Roberts LR, Gores GJ. Hepatocellular carcinoma. In Yamada T, Alpers DH, Kaplowitz N, et al., eds. Textbook of Gastroenterology, 4th ed. Lippincott Williams & Wilkins; Philadephia, 2003.

    Google Scholar 

  31. Wang JS, Groopman JD. DNA damage by mycotoxins. Mutat Res 1999;424:167–181.

    PubMed  CAS  Google Scholar 

  32. Ueno Y, Nagata S, Tsutsumi T, et al. Detection of microcystins, a blue-green algal hepatotoxin, in drinking water sampled in Haimen and Fusui, endemic areas of primary liver cancer in China, by highly sensitive immunoassay. Carcinogenesis 1996;17:1317–1321.

    Article  PubMed  CAS  Google Scholar 

  33. Sekijima M, Tsutsumi T, Yoshida T, et al. Enhancement of glutathione S-transferase placental-form positive liver cell foci development by microcystin-LR in aflatoxin B1-initiated rats. Carcinogenesis 1999;20:161–165.

    Article  PubMed  CAS  Google Scholar 

  34. Nakamoto Y, Guidotti LG, Kuhlen CV, et al. Immune pathogenesis of hepatocellular carcinoma. J Exp Med 1998;188: 341–350.

    Article  PubMed  CAS  Google Scholar 

  35. Chen PJ, Chen DS. Hepatitis B virus infection and hepatocellular carcinoma: molecular genetics and clinical perspectives. Semin Liver Dis 1999;19:253–262.

    Article  PubMed  CAS  Google Scholar 

  36. Feitelson MA. Hepatitis B virus in hepatocarcinogenesis. J Cell Physiol 1999;181:188–202.

    Article  PubMed  CAS  Google Scholar 

  37. Rabe C, Caselmann WH. Interaction of hepatitis B virus with cellular processes in liver carcinogenesis. Crit Rev Clin Lab Sci 2000;37:407–429.

    Article  PubMed  CAS  Google Scholar 

  38. Moriya K, Fujie H, Shintani Y, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998;4:1065–1067.

    Article  PubMed  CAS  Google Scholar 

  39. Ray RB, Lagging LM, Meyer K, et al. Transcriptional regulation of cellular and viral promoters by the hepatitis C virus core protein. Virus Res 1995;37:209–220.

    Article  PubMed  CAS  Google Scholar 

  40. Ray RB, Steele R, Meyer K, Ray R. Transcriptional repression of p53 promoter by hepatitis C virus core protein. J Biol Chem 1997;272:10,983–10,986.

    Article  PubMed  CAS  Google Scholar 

  41. Kato N, Yoshida H, Kioko Ono-Nita S, et al. Activation of intracellular signaling by hepatitis B and C viruses: C-viral core is the most potent signal inducer. Hepatology 2000;32:405–412.

    Article  PubMed  CAS  Google Scholar 

  42. Hayashi J, Aoki H, Kajino K, et al. Hepatitis C virus core protein activates the MAPK/ERK cascade synergistically with tumor promoter TPA, but not with epidermal growth factor or transforming growth factor alpha. Hepatology 2000;32:958–961.

    Article  PubMed  CAS  Google Scholar 

  43. Ray RB, Meyer K, Steele R, et al. Inhibition of tumor necrosis factor (TNF-alpha)-mediated apoptosis by hepatitis C virus core protein. J Biol Chem 1998;273:2256–2259.

    Article  PubMed  CAS  Google Scholar 

  44. Tai DI, Tsai SL, Chen YM, et al. Activation of nuclear factor kappaB in hepatitis C virus infection: implications for pathogenesis and hepatocarcinogenesis. Hepatology 2000;31:656–664.

    Article  PubMed  CAS  Google Scholar 

  45. Rehermann B. Interaction between the hepatitis C virus and the immune system. Semin Liver Dis 2000;20:127–141.

    Article  PubMed  CAS  Google Scholar 

  46. Ghosh AK, Steele R, Meyer K, et al. Hepatitis C virus NS5A protein modulates cell cycle regulatory genes and promotes cell growth. J Gen Virol 1999;80:1179–1183.

    PubMed  CAS  Google Scholar 

  47. Ghosh AK, Majumder M, Steele R, et al. Hepatitis C virus NS5A protein modulates transcription through a novel cellular transcription factor SRCAP. J Biol Chem 2000;275: 7184–7188.

    Article  PubMed  CAS  Google Scholar 

  48. Sakamuro D, Furukawa T, Takegami T. Hepatitis C virus nonstructural protein NS3 transforms NIH 3T3 cells. J Virol 1995;69:3893–3896.

    PubMed  CAS  Google Scholar 

  49. Chen CJ, Yu MW, Liaw YF, et al. Chronic hepatitis B carriers with null genotypes of glutathione S-transferase M1 and T1 polymorphisms who are exposed to aflatoxin are at increased risk of hepatocellular carcinoma. Am J Hum Genet 1996;59:128–134.

    PubMed  CAS  Google Scholar 

  50. Omer RE, Verhoef L, Van’t Veer P, et al. Peanut butter intake, GSTM1 genotype and hepatocellular carcinoma: a case-control study in Sudan. Cancer Causes Control 2001; 12:23–32.

    Article  PubMed  CAS  Google Scholar 

  51. Sun CA, Wang LY, Chen CJ, et al. Genetic polymorphisms of glutathione S-transferases M1 and T1 associated with susceptibility to aflatoxin-related hepatocarcinogenesis among chronic hepatitis B carriers: a nested case-control study in Taiwan. Carcinogenesis 2001;22:1289–1294.

    Article  PubMed  CAS  Google Scholar 

  52. Tiemersma EW, Omer RE, Bunschoten A, et al. Role of genetic polymorphism of glutathione-S-transferase T1 and microsomal epoxide hydrolase in aflatoxin-associated hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 2001;10:785–791.

    PubMed  CAS  Google Scholar 

  53. Sylla A, Diallo MS, Castegnaro J, Wild CP. Interactions between hepatitis B virus infection and exposure to aflatoxins in the development of hepatocellular carcinoma: a molecular epidemiological approach. Mutat Res 1999;428:187–196.

    PubMed  CAS  Google Scholar 

  54. El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 2001;33:62–65.

    Article  PubMed  CAS  Google Scholar 

  55. Kelloff GJ, Sigman CC, Johnson KM, et al. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer. Cancer Epidemiol Biomarkers Prev 2000;9:127–137.

    PubMed  CAS  Google Scholar 

  56. Blum HE. Hepatocellular carcinoma: susceptibility markers. IARC Sci Publ 2001;154:241–244.

    PubMed  CAS  Google Scholar 

  57. Hilleman MR. Overview of the pathogenesis, prophylaxis and therapeusis of viral hepatitis B, with focus on reduction to practical applications. Vaccine 2001;19:1837–1848.

    Article  PubMed  CAS  Google Scholar 

  58. Kane M. Global programme for control of hepatitis B infection. Vaccine 1995;13:S47–49.

    PubMed  Google Scholar 

  59. Kane MA. Status of hepatitis B immunization programmes in 1998. Vaccine 1998;16:S104–S108.

    Article  PubMed  Google Scholar 

  60. Chen HL, Chang MH, Ni YH, et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA 1996;276:906–908.

    Article  PubMed  CAS  Google Scholar 

  61. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997;336:1855–1859.

    Article  PubMed  CAS  Google Scholar 

  62. Wong DK, Cheung AM, O’Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis Be antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119: 312–323.

    PubMed  CAS  Google Scholar 

  63. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422–1427.

    Article  PubMed  CAS  Google Scholar 

  64. Lin SM, Sheen IS, Chien RN, et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999;29:971–975.

    Article  PubMed  CAS  Google Scholar 

  65. Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001;34:306–313.

    Article  PubMed  CAS  Google Scholar 

  66. Stark GR, Kerr IM, Williams BR, et al. How cells respond to interferons. Annu Rev Biochem 1998;67:227–264.

    Article  PubMed  CAS  Google Scholar 

  67. Merle P, Chevallier M, Levy R, et al. Preliminary results of interferon-alpha therapy on woodchuck hepatitis virus-induced hepatocarcinogenesis: possible benefit in female transgenic mice. J Hepatol 2001;34:562–569.

    Article  PubMed  CAS  Google Scholar 

  68. Oon CJ. Long-term survival following treatment of hepatocellular carcinoma in Singapore: evaluation of Wellferon in the prophylaxis of high-risk pre-cancerous conditions. Cancer Chemother Pharmacol 1992;31:S137–S142.

    Article  PubMed  Google Scholar 

  69. Mazzella G, Accogli E, Sottili S, et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996;24:141–147.

    Article  PubMed  CAS  Google Scholar 

  70. Fattovich G, Giustina G, Realdi G, et al. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1997;26:1338–1342.

    Article  PubMed  CAS  Google Scholar 

  71. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. International Interferon-alpha Hepatocellular Carcinoma Study Group. Lancet 1998;351:1535–1539.

    Google Scholar 

  72. Benvegnu L, Chemello L, Noventa F, et al. Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer 1998;83:901–909.

    Article  PubMed  CAS  Google Scholar 

  73. Ikeda K, Saitoh S, Suzuki Y, et al. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study. Cancer 1998;82:827–835.

    Article  PubMed  CAS  Google Scholar 

  74. Camma C, Giunta M, Andreone P, Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001;34:593–602.

    Article  PubMed  CAS  Google Scholar 

  75. Lechmann M, Liang TJ. Vaccine development for hepatitis C. Semin Liver Dis 2000;20:211–1226.

    Article  PubMed  CAS  Google Scholar 

  76. Lavanchy D. Hepatitis C: public health strategies. J Hepatol 1999;31:146–151.

    Article  PubMed  Google Scholar 

  77. Marcellin P. Hepatitis C: the clinical spectrum of the disease. J Hepatol 1999;31:9–16.

    Article  PubMed  Google Scholar 

  78. Hoofnagle JH, di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997;336:347–356.

    Article  PubMed  CAS  Google Scholar 

  79. Heathcote J. Antiviral therapy for patients with chronic hepatitis C. Semin Liver Dis 2000;20:185–199.

    Article  PubMed  CAS  Google Scholar 

  80. Kozlowski A, Harris JM. Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C. J Control Release 2001;72:217–224.

    Article  PubMed  CAS  Google Scholar 

  81. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666–1672.

    Article  PubMed  CAS  Google Scholar 

  82. Lindsay KL, Trepo C, Heintges T, et al. Arandomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395–403.

    Article  PubMed  CAS  Google Scholar 

  83. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358: 958–965.

    Article  PubMed  CAS  Google Scholar 

  84. Gordon SC. Treatment of viral hepatitis—2001. Ann Med 2001;33:385–390.

    Article  PubMed  CAS  Google Scholar 

  85. Camma C, Giunta M, Linea C, Pagliaro L. The effect of interferon on the liver in chronic hepatitis C: a quantitative evaluation of histology by meta-analysis. J Hepatol 1997;26:1187–1199.

    Article  PubMed  CAS  Google Scholar 

  86. Poynard T, Moussalli J, Ratziu V, et al. Effect of interferon therapy on the natural history of hepatitis C virus-related cirrhosis and hepatocellular carcinoma. Clin Liver Dis 1999;3:869–881.

    Article  PubMed  CAS  Google Scholar 

  87. Poynard T, McHutchison J, Davis GL, et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000;32: 1131–1137.

    Article  PubMed  CAS  Google Scholar 

  88. Poynard T, Moussali J, Ratziu V, et al. Effects of interferon therapy in “non responder” patients with chronic hepatitis C. J Hepatol 1999;31:178–183.

    Article  PubMed  Google Scholar 

  89. Kuwana K, Ichida T, Kamimura T, et al. Risk factors and the effect of interferon therapy in the development of hepatocellular carcinoma: a multivariate analysis in 343 patients. J Gastroenterol Hepatol 1997;12:149–155.

    Article  PubMed  CAS  Google Scholar 

  90. Imai Y, Kawata S, Tamura S, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med 1998;129:94–99.

    PubMed  CAS  Google Scholar 

  91. Kasahara A, Hayashi N, Mochizuki K, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology 1998;27:1394–1402.

    Article  PubMed  CAS  Google Scholar 

  92. Camma C, Di Marco V, Lo Iacono O, et al. Long-term course of interferon-treated chronic hepatitis C. J Hepatol 1998;28:531–537.

    Article  PubMed  CAS  Google Scholar 

  93. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999;131:174–181.

    PubMed  CAS  Google Scholar 

  94. Ikeda K, Saitoh S, Arase Y, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999;29:1124–1130.

    Article  PubMed  CAS  Google Scholar 

  95. Okanoue T, Itoh Y, Minami M, et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. J Hepatol 1999;30:653–659.

    Article  PubMed  CAS  Google Scholar 

  96. Shindo M, Ken A, Okuno T. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy. Cancer 1999;85:1943–1950.

    PubMed  CAS  Google Scholar 

  97. Tanaka H, Tsukuma H, Kasahara A, et al. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000;87:741–749.

    Article  PubMed  CAS  Google Scholar 

  98. Emanuel EJ, Miller FG. The ethics of placebo-controlled trials—a middle ground. N Engl J Med 2001;345:915–919.

    Article  PubMed  CAS  Google Scholar 

  99. Wild CP, Hall AJ. Primary prevention of hepatocellular carcinoma in developing countries. Mutat Res 2000;462:381–393.

    Article  PubMed  CAS  Google Scholar 

  100. Kwak MK, Egner PA, Dolan PM, et al. Role of phase 2 enzyme induction in chemoprotection by dithiolethiones. Mutat Res 2001;480–481:305–315.

    PubMed  Google Scholar 

  101. Kensler TW, Groopman JD, Sutter TR, et al. Development of cancer chemopreventive agents: oltipraz as a paradigm. Chem Res Toxicol 1999;12:113–126.

    Article  PubMed  CAS  Google Scholar 

  102. Jacobson LP, Zhang BC, Zhu YR, et al. Oltipraz chemoprevention trial in Qidong, People’s Republic of China: study design and clinical outcomes. Cancer Epidemiol Biomarkers Prev 1997;6:257–265.

    PubMed  CAS  Google Scholar 

  103. Kensler TW, He X, Otieno M, et al. Oltipraz chemoprevention trial in Qidong, People’s Republic of China: modulation of serum aflatoxin albumin adduct biomarkers. Cancer Epidemiol Biomarkers Prev 1998;7:127–134.

    PubMed  CAS  Google Scholar 

  104. Wang JS, Shen X, He X, et al. Protective alterations in phase 1 and 2 metabolism of aflatoxin B1 by oltipraz in residents of Qidong, People’s Republic of China. J Natl Cancer Inst 1999;91:347–354.

    Article  PubMed  CAS  Google Scholar 

  105. Mato JM, Alvarez L, Ortiz P, Pajares MA. S-adenosylmethionine synthesis: molecular mechanisms and clinical implications. Pharmacol Ther 1997;73:265–280.

    Article  PubMed  CAS  Google Scholar 

  106. Zingg JM, Jones PA. Genetic and epigenetic aspects of DNA methylation on genome expression, evolution, mutation and carcinogenesis. Carcinogenesis 1997;18:869–882.

    Article  PubMed  CAS  Google Scholar 

  107. Pascale RM, Simile MM, Feo F. Genomic abnormalities in hepatocarcinogenesis. Implications for a chemopreventive strategy. Anticancer Res 1993;13:1341–1356.

    PubMed  CAS  Google Scholar 

  108. Pascale RM, Marras V, Simile MM, et al. Chemoprevention of rat liver carcinogenesis by S-adenosyl-L-methionine: a long-term study. Cancer Res 1992;52:4979–4986.

    PubMed  CAS  Google Scholar 

  109. Gerbracht U, Eigenbrodt E, Simile MM, et al. Effect of S-adenosyl-L-methionine on the development of preneoplastic foci and the activity of some carbohydrate metabolizing enzymes in the liver, during experimental hepatocarcinogenesis. Anticancer Res 1993;13:1965–1972.

    PubMed  CAS  Google Scholar 

  110. Pascale RM, Simile MM, De Miglio MR, et al. Chemoprevention by S-adenosyl-L-methionine of rat liver carcinogenesis initiated by 1,2-dimethylhydrazine and promoted by orotic acid. Carcinogenesis 1995;16:427–430.

    Article  PubMed  CAS  Google Scholar 

  111. Ansorena E, Garcia-Trevijano ER, Martinez-Chantar ML, et al. S-adenosylmethionine and methylthioadenosine are antiapoptotic in cultured rat hepatocytes but proapoptotic in human hepatoma cells. Hepatology 2002;35:274–280.

    Article  PubMed  CAS  Google Scholar 

  112. Cai J, Sun WM, Hwang JJ, Stain SC, Lu SC. Changes in S-adenosylmethionine synthetase in human liver cancer: molecular characterization and significance. Hepatology 1996;24:1090–1097.

    Article  PubMed  CAS  Google Scholar 

  113. Cai J, Mao Z, Hwang JJ, Lu SC. Differential expression of methionine adenosyltransferase genes influences the rate of growth of human hepatocellular carcinoma cells. Cancer Res 1998;58:1444–1450.

    PubMed  CAS  Google Scholar 

  114. Yang H, Huang ZZ, Wang J, Lu SC. The role of c-Myb and Sp1 in the up-regulation of methionine adenosyltransferase 2A gene expression in human hepatocellular carcinoma. Faseb J 2001;15:1507–1516.

    Article  PubMed  CAS  Google Scholar 

  115. Mato JM, Camara J, Fernandez de Paz J, et al. SAdenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999;30:1081–1089.

    Article  PubMed  CAS  Google Scholar 

  116. Vainio H. Is COX-2 inhibition a panacea for cancer prevention? Int J Cancer 2001;94:613–614.

    Article  PubMed  CAS  Google Scholar 

  117. Koga H, Sakisaka S, Ohishi M, et al. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology 1999;29: 688–696.

    Article  PubMed  CAS  Google Scholar 

  118. Bae SH, Jung ES, Park YM, et al. Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398. Clin Cancer Res 2001;7:1410–1418.

    PubMed  CAS  Google Scholar 

  119. Rahman MA, Dhar DK, Masunaga R, et al. Sulindac and exisulind exhibit a significant antiproliferative effect and induce apoptosis in human hepatocellular carcinoma cell lines. Cancer Res 2000;60:2085–2089.

    PubMed  CAS  Google Scholar 

  120. Jaiswal M, LaRusso NF, Gores GJ. Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. Am J Physiol Gastrointest Liver Physiol 2001;281:G626–634.

    PubMed  CAS  Google Scholar 

  121. Ahn B, Ohshima H. Suppression of intestinal polyposis in Apc(Min/+) mice by inhibiting nitric oxide production. Cancer Res 2001;61:8357–8360.

    PubMed  CAS  Google Scholar 

  122. Rao CV, Indranie C, Simi B, et al. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Cancer Res 2002;62:165–170.

    PubMed  CAS  Google Scholar 

  123. Kane JM, 3rd, Shears LL, 2nd, Hierholzer C, et al. Chronic hepatitis C virus infection in humans: induction of hepatic nitric oxide synthase and proposed mechanisms for carcinogenesis. J Surg Res 1997;69: 321–324.

    Article  PubMed  CAS  Google Scholar 

  124. Terasaki S, Kaneko S, Kobayashi K, et al. Histological features predicting malignant transformation of nonmalignant hepatocellular nodules: a prospective study. Gastroenterology 1998;115:1216–1222.

    Article  PubMed  CAS  Google Scholar 

  125. Kojiro M. Premalignant lesions of hepatocellular carcinoma: pathologic viewpoint. J Hepatobiliary Pancreat Surg 2000;7:535–541.

    Article  PubMed  CAS  Google Scholar 

  126. Zondervan PE, Wink J, Alers JC, et al. Molecular cytogenetic evaluation of virus-associated and non-viral hepatocellular carcinoma: analysis of 26 carcinomas and 12 concurrent dysplasias. J Pathol 2000;192:207–215.

    Article  PubMed  CAS  Google Scholar 

  127. Bannasch P, Nehrbass D, Kopp-Schneider A. Significance of hepatic preneoplasia for cancer chemoprevention. IARC Sci Publ 2001;154:223–240.

    PubMed  CAS  Google Scholar 

  128. Qian C, Drozdzik M, Caselmann WH, Prieto J. The potential of gene therapy in the treatment of hepatocellular carcinoma. J Hepatol 2000;32:344–351.

    Article  PubMed  CAS  Google Scholar 

  129. Baba M, Iishi H, Tatsuta M. In vivo electroporetic transfer of bcl-2 antisense oligonucleotide inhibits the development of hepatocellular carcinoma in rats. Int J Cancer 2000;85:260–266.

    PubMed  CAS  Google Scholar 

  130. Baba M, Iishi H, Tatsuta M. Transfer of bcl-xs plasmid is effective in preventing and inhibiting rat hepatocellular carcinoma induced by N-nitrosomorpholine. Gene Therapy 2001;8:1149–1156.

    Article  PubMed  CAS  Google Scholar 

  131. Tennant BC. Animal models of hepadnavirus-associated hepatocellular carcinoma. Clin Liver Dis 2001;5:43–68.

    Article  PubMed  CAS  Google Scholar 

  132. Wang HP, Zhang L, Dandri M, Rogler CE. Antisense down-regulation of N-myc1 in woodchuck hepatoma cells reverses the malignant phenotype. J Virol 1998;72:2192–2198.

    PubMed  CAS  Google Scholar 

  133. Ko S, Nakajima Y, Kanehiro H, et al. Significant influence of accompanying chronic hepatitis status on recurrence of hepatocellular carcinoma after hepatectomy. Result of multivariate analysis. Ann Surg 1996;224:591–595.

    Article  PubMed  CAS  Google Scholar 

  134. Tung-Ping Poon R, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 2000;232: 10–24.

    Article  PubMed  CAS  Google Scholar 

  135. Ikeda K, Arase Y, Saitoh S, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000;32:228–232.

    Article  PubMed  CAS  Google Scholar 

  136. Kubo S, Nishiguchi S, Hirohashi K, et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. Arandomized, controlled trial. Ann Intern Med 2001;134:963–967.

    PubMed  CAS  Google Scholar 

  137. Everson GT. Maintenance interferon for chronic hepatitis C: more issues than answers? Hepatology 2000;32: 436–438.

    Article  PubMed  CAS  Google Scholar 

  138. Hansen LA, Sigman CC, Andreola F, et al. Retinoids in chemoprevention and differentiation therapy. Carcinogenesis 2000;21:1271–1279.

    Article  PubMed  CAS  Google Scholar 

  139. Muto Y, Moriwaki H. Antitumor activity of vitamin A and its derivatives. J Natl Cancer Inst 1984;73:1389–1393.

    PubMed  CAS  Google Scholar 

  140. Muto Y, Moriwaki H, Ninomiya M, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 1996;334:1561–1567.

    Article  PubMed  CAS  Google Scholar 

  141. Chen YJ, Yeh SH, Chen JT, et al. Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma. Gastroenterology 2000;119:431–440.

    Article  PubMed  CAS  Google Scholar 

  142. Muto Y, Moriwaki H, Saito A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med 1999;340:1046–1047.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre de Recherche du CHUM, Hôpital Saint Luc, Montreal, Canada

    Ziad Hassoun MD

  2. Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN

    Gregory J. Gores MD

Authors
  1. Ziad Hassoun MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gregory J. Gores MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Biomedical Imaging Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD

    Gary J. Kelloff MD

  2. Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD

    Ernest T. Hawk MD, MPH

  3. CCS Associates, Mountain View, CA

    Caroline C. Sigman PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Hassoun, Z., Gores, G.J. (2005). Clinical Strategies for Chemoprevention of Liver Cancer. In: Kelloff, G.J., Hawk, E.T., Sigman, C.C. (eds) Cancer Chemoprevention. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-59259-768-0_37

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-768-0_37

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-077-9

  • Online ISBN: 978-1-59259-768-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation